Impact of Nebivolol on Central Aortic Pressure

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01051947

Enrollment

Registered

2010-01-20

Start date

2009-12-31

Completion date

2010-05-31

Last updated

2011-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Aortic Pressure

Keywords

Nebivolol, Metoprolol, central aortic pressure, hypertension

Brief summary

A randomized, cross-over, single-blind study to compare the effects of nebivolol and metoprolol on central aortic pressure and peripheral brachial pressure in patients with stable cardiovascular disease.

Interventions

DRUGNebivolol

10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks

DRUGMetoprolol

dosage prescribed prior to starting on study

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

45 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Subjects with history of hypertension * Subjects who have received metoprolol for a minimum of 3 months

Exclusion criteria

* Patients who have had an acute myocardial infarction, coronary revascularization or who have been hospitalized for heart failure or cardiac arrhythmia in the past 6 months

Design outcomes

Primary

Measure	Time frame	Description
Stable blood pressure	6 months	Subjects will be randomized to nebivolol or metoprolol. Their medication will be titrated so that their blood pressure is within 10% of their initial reading.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026